Table 4. Influential factors for changes of defined daily dose of anti-hypertensive agents at 12 months.
| Univariate | Multivariate | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variables | Regression coefficient | Standard error | t value | 95%CI | p value | Regression coefficient | Standard error | t value | 95%CI | p value |
| Age | -0.0014 | 0.0049 | -0.29 | -0.011 to 0.0083 | 0.77 | -0.0085 | 0.0056 | -1.51 | -0.020 to 0.0026 | 0.13 |
| Male gender | -0.015 | 0.060 | -0.26 | -0.13 to 0.10 | 0.80 | 0.019 | 0.058 | 0.33 | -0.095 to 0.13 | 0.74 |
| Dialysis vintage | 0.000071 | 0.00073 | 0.10 | -0.0014 to 0.0015 | 0.92 | 0.000049 | 0.00075 | -0.07 | -0.0015 to 0.0014 | 0.95 |
| DM | 0.079 | 0.061 | 1.29 | -0.042 to 0.20 | 0.20 | 0.062 | 0.061 | 1.01 | -0.058 to 0.18 | 0.31 |
| Past history of CVD | -0.0046 | 0.064 | -0.07 | -0.13 to 0.12 | 0.94 | 0.0097 | 0.060 | 0.16 | -0.11 to 0.13 | 0.87 |
| Dry weight at baseline | -0.00022 | 0.0054 | -0.04 | -0.011 to 0.010 | 0.97 | |||||
| Predialysis SBP at baseline | 0.0022 | 0.0024 | 0.91 | -0.0025 to 0.0069 | 0.37 | 0.0028 | 0.0032 | 0.89 | -0.0035 to 0.0092 | 0.38 |
| Predialysis DBP at baseline | 0.0037 | 0.0041 | 0.89 | -0.0044 to 0.012 | 0.37 | 0.0017 | 0.0057 | 0.30 | -0.0095 to 0.013 | 0.76 |
| Hemoglobin at baseline | -0.075 | 0.050 | -1.49 | -0.17 to 0.024 | 0.14 | |||||
| BUN at baseline | -0.0009 | 0.0039 | -0.23 | -0.0085 to 0.0067 | 0.82 | |||||
| Cr at baseline | 0.011 | 0.022 | 0.49 | -0.032 to 0.053 | 0.62 | -0.016 | 0.024 | -0.67 | -0.063 to 0.031 | 0.51 |
| Serum albumin at baseline | -0.16 | 0.19 | -0.84 | -0.55 to 0.22 | 0.40 | -0.11 | 0.20 | -0.53 | -0.49 to 0.28 | 0.59 |
| TC at baseline | -0.00062 | 0.0017 | -0.35 | -0.0041 to 0.0028 | 0.72 | |||||
| HDL at baseline | -0.0031 | 0.0027 | -1.16 | -0.0083 to 0.0022 | 0.25 | |||||
| TG at baseline | 0.0010 | 0.00093 | 1.07 | -0.00083 to 0.0028 | 0.28 | |||||
| Ferritin at baseline | 0.00044 | 0.00052 | 0.84 | -0.00059 to 0.0015 | 0.40 | |||||
| CRP at baseline | -0.036 | 0.090 | -0.40 | -0.21 to 0.14 | 0.69 | -0.068 | 0.081 | -0.84 | -0.23 to 0.091 | 0.40 |
| B2M at baseline | 0.0045 | 0.0086 | 0.52 | -0.013 to 0.022 | 0.60 | |||||
| DDD at baseline | -0.27 | 0.037 | -7.21 | -0.34 to -0.19 | <0.01 | -0.32 | 0.038 | -8.38 | -0.40 to -0.25 | <0.01 |
| E-HD | -0.17 | 0.059 | -2.95 | -0.29 to -0.057 | <0.01 | -0.27 | 0.057 | -4.73 | -0.38 to -0.16 | <0.01 |
DM, diabetes mellitus; CVD, cardiovascular disease; SBP, systolic blood pressure, DBP, diastolic blood pressure; BUN, blood urea nitrogen; Cr, serum creatinine; TC, total cholesterol; HDL, high density lipoprotein; TG, triglyceride; CRP, C-reactive protein; B2m, B2microglobulin; DDD, defined daily dose of anti-hypertensive agents; E-HD, electrolyzed water hemodialysis.
In multivariate analysis, in addition to factors with p-value less than 0.1 by univariate analysis, clinical-relevant possible influential factors for the prescriptions of anti-hypertensive agents were employed for analysis. Those include dialysis-related factors, such as, age, gender, dialysis vintage, Cr at baseline, cardiovascular and mortality-related factors, such as, presence of DM, history of CVD, nutrition and inflammation (serum albumin and CRP at baseline), and blood pressure-related factors, such as, pre-dialysis SBP and DBP.